

28 October 2013

ASX ANNOUNCEMENT

APPOINTMENT OF SCIENTIFIC CONSULTANT

Actinogen Limited (ASX: ACW) is pleased to confirm the appointment of Dr David Keast to the role of scientific consultant.

Dr Keast was an integral member of the Actinogen team and headed up the research and development of Actinogen's ongoing Actinomycetes projects. Dr Keast was a founder in many of the Company's current research streams and has invaluable knowledge and experience in this specialist field.

Dr Keast will play a key role in the relocation of the Company's laboratory to new premises due to the refurbishment currently underway at the QEII medical Centre; the re-establishment of the research team, and also be the specialist consultant to the projects moving forward.

Dr Keast was involved in the previous project trials, making his appointment seamless in transition. The Company welcomes Dr Keast back to the Actinogen team and is extremely pleased to have retained his invaluable services.

About Dr David Keast

CDA, BSc, MSc, PhD, MASM.

Professor Keast was on the staff of the University of Western Australia for more than 34 years. He is currently an Honorary Research Fellow in microbiology at the University of Western Australia. He has over 225 publications, reviews and chapters in international scientific journals in the areas of microbiology, immunology and sports science. He has wide experience in reviewing research applications for medical, cancer research and biological research for the major granting bodies in Australia. He has broad experience in administration, particularly at higher degree scholarship levels and reviewed and examined research at all levels. He has experience in contract research and patent development.

During the 1980s Dr Keast developed and ran a large actinomycetes isolation, screening and research and development program at the University of Western Australia, which was financed by the multi-national pharmaceutical company, Merck Sharp and Dohme.